Abstract: Use of a compound corresponding to formula (I) in which R represents hydrogen or a group chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene, cycloalkylidyne and —CONH2 groups, and the —COR? and —COOR? groups, in which R? is chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene and cycloalkylidyne groups, it being possible for said groups R and/or R? to be substituted and/or interrupted with -0-, —COO—, —OCO—, —NHCO— or —CONH— functions, or a pharmaceutically acceptable salt of said compound, for obtaining a medicament for use in the treatment of faecal incontinence.

Abstract: Crystal form of besipirdine chlorhydrate (Form I) corresponding to the Formula (A) below: the aforementioned form being characterized at least by one of the following physico-chemical properties: a) In FTIR, it displays at least the following absorption bands of the infrared spectrum: 778, 1198, 1121, but not the following absorption bands of the infrared spectrum: 3395, 1583, 732, the aforementioned bands being expressed in cm?1 at ±5 cm?1; b) In PXRD, it shows at least the following reflections, which are the most intense ones but whose intensity hereafter is given for information only: Formula (II) c) In DSC, it displays at least an endothermic peak at 187.3±2.0° C. using 5° C./min scanning conditions, and a fusion enthalpy ?H of 130.4±2.0 J/g. The invention also relates to the processes used for the preparation of form I as well as its applications in urology.

Abstract: Use of a compound corresponding to formula (I): in which R represents hydrogen or a group chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene, cycloalkylidyne and —CONH2 groups, and —COR? and —COOR? groups, where R? is chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene and cycloalkylidyne groups, it being possible for said groups R and/or R? to be substituted and/or interrupted with —O—, —COO—, —OCO—, —NHCO— or —CONH— functions, or a pharmaceutically acceptable salt of said compound, for obtaining a medicinal product for use in the treatment of stress urinary incontinence and of mixed urinary incontinence.

Abstract: Use of a compound corresponding to formula (I), for obtaining a medicinal product for use in the treatment of the symptoms of bladder irritation.

Abstract: The invention relates to a method for in vitro evaluation of the aggressiveness of tumor cells by measuring the level of expression of all or part of a gene coding for semaphorin 3A in healthy epithelial cells and in epithelial tumor cells. The invention also relates to a method of inhibiting the invasive power of epithelial tumor cells, consisting in increasing the levels of semaphorin 3A levels present in and/or in the vicinity of said epithelial tumor cells.